UNITED STATES SECURITIES AND EXCHANGE COMMISSION April 22, 2013

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

SciClone Pharmaceuticals, Inc.

File No. 000-19825 - CF#29575

SciClone Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibit to a Form 10-K filed on April 1, 2013.

Based on representations by SciClone Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:

Exhibit 10.42

through March 31, 2016

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Laura Crotty Special Counsel